Proc Natl Acad Sci 96:4330–4335ĭouglas RG, Sharma RK, Masuyer G et al (2014) Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. ![]() Biochemistry 16:5484–5491ĭive V, Cotton J, Yiotakis A et al (1999) RXP407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Carboxyalkanoyl and mercaptoalkanoyl amino acids. J Mol Biol 357:964–974Ĭushman DW, Cheung HS, Sabo EF et al (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Am J Cardiol 83:43–47Ĭorradi HR, Schwager SL, Nchinda AT et al (2006) Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. Clin Sci (Lond) 127:57–63Ĭashin-Hemphill L, Holmvang G, Chan RC et al (1999) Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Pharmacol Rev 65:1–46īurger D, Reudelhuber TL, Mahajan A et al (2014) Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Curr Opin Pharmacol 11:105–111īernstein KE, Ong FS, Blackwell WL et al (2012) A modern understanding of the traditional and non-traditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 71:539–570īernstein KE, Shen XZ, Gonzalez-Villalobos RA et al (2011) Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). ![]() JAMA 288:2981–2997Īrendse LB, Danser AHJ, Poglitsch M et al (2019) Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. ![]() The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002) Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Nat Rev Drug Discov 2:891–902ĪLLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Acharya KR, Sturrock ED, Riordan JF et al (2003) ACE revisited: a new target for structure-based drug design.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |